First-generation EGFR tyrosine kinase inhibitors (TKIs) (e.g., gefitinib and erlotinib) and second-generation TKIs (e.g., neratinib and dacomitinib) were shown to prolong overall survival in BMs from non-small cell lung cancer (NSCLC) with EGFR mutations [44,45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.